Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and preparation method of cervical cancer therapeutic vaccine

A therapeutic vaccine, Listeria monocytogenes technology, applied in the field of genetic engineering, can solve the problems of long immunization cycle and poor immunization effect, and achieve the effect of not easy to lose, no risk of antibiotic resistance, and efficient tumor killing mechanism

Pending Publication Date: 2021-03-23
ZHEJIANG FORESTRY UNIVERSITY
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The vaccines currently used against tumors are mainly traditional inactivated vaccines and subunit vaccines, which have disadvantages such as long immune cycle and poor immune effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and preparation method of cervical cancer therapeutic vaccine
  • Cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and preparation method of cervical cancer therapeutic vaccine
  • Cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and preparation method of cervical cancer therapeutic vaccine

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0052] Still further, the embodiments of the present invention also provide a method for preparing the above-mentioned recombinant attenuated Listeria monocytogenes vaccine, comprising the following steps:

[0053] (1) Synthesize the complete open reading frame (ORF) sequence of the HPV 16 type E7 gene;

[0054] (2) Construction of the homologous recombination plasmid pSL1854 used in the present invention;

[0055] (3) preparing attenuated and single-increased Listeria d competent cells;

[0056] (4) using the recombinant plasmid prepared in step (2) to perform electrotransformation on the competent cells prepared in step (3);

[0057] (5) Screening of the vaccine (LADS-Echo7) of the present invention.

[0058] In one embodiment, the step (1) specifically includes:

[0059] Download the ORF sequence of HPV type 16 E7 gene from NCBI, the length is 297bp, and entrust Suzhou Jinweizhi Biotechnology Company to synthesize the sequence.

[0060] In one embodiment, the step (2) s...

Embodiment 1

[0076] Example 1 Construction of recombinant Listeria vaccine LADS-Echo7

[0077] 1. Synthesis of full-length gene sequence of HPV type 16 E7 and construction of homologous recombination plasmid

[0078] Download the complete open reading frame (ORF) sequence (as shown in SEQ ID NO.1) of the HPV type 16 E7 gene from the Genbank database, and entrust Suzhou Jinweizhi Biotechnology Company to synthesize the sequence. PCR was used to amplify fragments A (498bp, amplification primers P2 and P3) and B (500bp, amplification primers P4 and P5) respectively containing restriction sites KpnI and PstI using the whole genome DNA of Lemo-C07 as a template; At the same time, fragment E7 was amplified using the complete sequence of the synthesized E7 gene as a template (amplification primers were P6 and P7). On this basis, the three fragments were joined together by overlapping PCR technique (SOE-PCR) to obtain the target fragment of "A-E7-B" (sequence shown in SEQ ID NO.2). Using KpnI an...

Embodiment 2

[0089] Example 2 Efficacy Evaluation of Recombinant Listeria Vaccine LADS-Echo7 Treating Mouse Model of Cervical Cancer

[0090] 1. Verification of expression of recombinant tumor antigen E7 protein by LADS-Echo7

[0091] Pick a single colony in 5mL BHI liquid medium and place it on a shaker at 37°C for overnight culture. Take 1 mL of the overnight culture and transfer it to 100 mL of BHI liquid medium, shake and culture at 37°C for 8-9 hours, centrifuge and filter the supernatant; precipitate the filtered supernatant with trichloroacetic acid overnight, 12000rpm, 20min, 4 Centrifuge at ℃ to discard the supernatant, resuspend the pellet with 1mL 1M NaOH, centrifuge to take the supernatant, which is the secreted protein; after centrifugation, the pellet is washed with 50mM PBS and resuspended with 1mL Lister lysate, broken by a homogenizer, and centrifuged to take the supernatant. Qing is a cytoplasmic protein. After measuring and quantifying the secreted protein and cytoplas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and a preparation method of the cervical cancer therapeutic vaccine, and relates tothe field of genetic engineering. The attenuated Listeria monocytogenes Lemo-C07 are taken as a background, and a virulence factor LLO protein of the strain carries two key mutant amino acid sites, sothat the virulence of the strain is greatly reduced, but part of the proliferation ability in the cells is still retained. According to the vaccine, on the basis of the attenuated Listeria monocytogenes, a molecular biological technique is utilized to integrate a full-length gene of a specific antigen E7 of the cervical cancer to the downstream part of an LLO gene of the Listeria monocytogenes, thereby constructing and obtaining the recombinant attenuated Listeria monocytogenes containing the tumor specific antigen E7. The vaccine has the capabilities of presenting the specific antigen and activating the anti-tumor cellular immunity of the body, and has the remarkable tumor treatment effect.

Description

technical field [0001] The invention relates to the technical field of genetic engineering, in particular to a therapeutic vaccine for cervical cancer based on recombinant attenuated Listeria monocytogenes and a preparation method thereof. Background technique [0002] Cervical cancer is the most common gynecological malignancy. The high-incidence age of carcinoma in situ is 30-35 years old, and that of invasive carcinoma is 45-55 years old. In recent years, the onset tends to be younger. The widespread application of cervical cytology screening in recent decades has enabled early detection and treatment of cervical cancer and precancerous lesions, and the incidence and mortality of cervical cancer have dropped significantly. Traditional methods of treating cancer are mainly surgical resection, radiotherapy, chemotherapy and therapeutic vaccines. Surgical resection, radiotherapy, and chemotherapy are prone to disadvantages such as metastasis and recurrence. In contrast, va...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/21C12N15/37C12N15/74A61K39/12A61P31/20A61P35/00C12R1/01
CPCC07K14/005C12N15/74A61K39/12A61P31/20A61P35/00C12N2710/20022C12N2710/20034A61K2039/523
Inventor 宋厚辉程昌勇孙静徐加利韩月雷蕾
Owner ZHEJIANG FORESTRY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com